Chronic Heart Failure
Conditions
Interventions
Qili Qiangxin capsule Group:Qili Qiangxin capsule + basal treatment (ACEI or ARB/ß-blockers/diuretics/with or without digoxin)
Placebo Group:Placebo+basal treatment (ACEI or ARB/ß-blockers/diuretics/with or without digoxin)
Sponsors
Shuguang hospital affiliated to Shanghai university of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Consistent with chronic heart failure diagnosis in patients with class II-III heart failure; The ages of 40-80 years old; heart-kidney yang deficiency syndrome; Willing to take Chinese medicine, and non-allergic.
Exclusion criteria
Exclusion criteria: Heart failure due to pericardial disease, arrhythmiaHeart failure caused due to non-cardiac causesHeart failure due to pulmonary embolism, or kidney, liver and other vital organs function failure; Associated with severe primary diseases of the liver, kidney and the endocrine, respiratory, hematopoietic system;Patients with severe infection, with advanced malignancies; the combined mental disorders and do not want to take Chinese medicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac function;TCM symptoms evaluation;Efficacy evaluation;Western medicine less stop rate;Cardiovascular all-cause mortality;Years of worsening heart failure number of admission;6-minute walk test;Quality of life survey;Echocardiography;BNP;Hypersensitivity CRP;Adverse events and adverse reactions;Safety Evaluation; | — |
Countries
China
Contacts
Public ContactWang Xiaolong
Outcome results
None listed